Cargando…

Postoperative metastasis prediction based on portal vein circulating tumor cells detected by flow cytometry in periampullary or pancreatic cancer

PURPOSE: The aim of this study was to evaluate the value of flow cytometry (FCM) detection of portal vein circulating tumor cells (CTCs) in predicting postoperative metastasis. METHODS: Samples of portal venous blood and peripheral blood were collected from 39 patients during surgery, and CTCs were...

Descripción completa

Detalles Bibliográficos
Autores principales: Tao, Lianyuan, Su, Li, Yuan, Chunhui, Ma, Zhaolai, Zhang, Lingfu, Bo, Shiping, Niu, Yunyun, Lu, Sijia, Xiu, Dianrong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6689556/
https://www.ncbi.nlm.nih.gov/pubmed/31496801
http://dx.doi.org/10.2147/CMAR.S210332
_version_ 1783443042674409472
author Tao, Lianyuan
Su, Li
Yuan, Chunhui
Ma, Zhaolai
Zhang, Lingfu
Bo, Shiping
Niu, Yunyun
Lu, Sijia
Xiu, Dianrong
author_facet Tao, Lianyuan
Su, Li
Yuan, Chunhui
Ma, Zhaolai
Zhang, Lingfu
Bo, Shiping
Niu, Yunyun
Lu, Sijia
Xiu, Dianrong
author_sort Tao, Lianyuan
collection PubMed
description PURPOSE: The aim of this study was to evaluate the value of flow cytometry (FCM) detection of portal vein circulating tumor cells (CTCs) in predicting postoperative metastasis. METHODS: Samples of portal venous blood and peripheral blood were collected from 39 patients during surgery, and CTCs were detected by FCM, with confirmation by laser confocal microscopy and single-cell sequencing. RESULTS: Among all patients, a portal EpCAM+CD45- percentage ≥24.5×10(−4) (P=0.06), peripheral EpCAM+CD45- count ≥97/5 mL (P=0.034), peripheral EpCAM+CD45- percentage ≥4.4×10(−4) (P=0.042), and CA242≥3.5 U/mL (P=0.027) were significant predictors of metastasis. Further analysis showed that the portal EpCAM+CD45- ratio ≥24.5×10(−4) is a predictor of metastasis (P=0.025) in pancreatic cancer after curative resection. CONCLUSION: CTCs detected by FCM in portal venous blood are of significant value for the prediction of postoperative metastasis in pancreatic or periampullary tumors.
format Online
Article
Text
id pubmed-6689556
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-66895562019-09-06 Postoperative metastasis prediction based on portal vein circulating tumor cells detected by flow cytometry in periampullary or pancreatic cancer Tao, Lianyuan Su, Li Yuan, Chunhui Ma, Zhaolai Zhang, Lingfu Bo, Shiping Niu, Yunyun Lu, Sijia Xiu, Dianrong Cancer Manag Res Original Research PURPOSE: The aim of this study was to evaluate the value of flow cytometry (FCM) detection of portal vein circulating tumor cells (CTCs) in predicting postoperative metastasis. METHODS: Samples of portal venous blood and peripheral blood were collected from 39 patients during surgery, and CTCs were detected by FCM, with confirmation by laser confocal microscopy and single-cell sequencing. RESULTS: Among all patients, a portal EpCAM+CD45- percentage ≥24.5×10(−4) (P=0.06), peripheral EpCAM+CD45- count ≥97/5 mL (P=0.034), peripheral EpCAM+CD45- percentage ≥4.4×10(−4) (P=0.042), and CA242≥3.5 U/mL (P=0.027) were significant predictors of metastasis. Further analysis showed that the portal EpCAM+CD45- ratio ≥24.5×10(−4) is a predictor of metastasis (P=0.025) in pancreatic cancer after curative resection. CONCLUSION: CTCs detected by FCM in portal venous blood are of significant value for the prediction of postoperative metastasis in pancreatic or periampullary tumors. Dove 2019-08-06 /pmc/articles/PMC6689556/ /pubmed/31496801 http://dx.doi.org/10.2147/CMAR.S210332 Text en © 2019 Tao et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Tao, Lianyuan
Su, Li
Yuan, Chunhui
Ma, Zhaolai
Zhang, Lingfu
Bo, Shiping
Niu, Yunyun
Lu, Sijia
Xiu, Dianrong
Postoperative metastasis prediction based on portal vein circulating tumor cells detected by flow cytometry in periampullary or pancreatic cancer
title Postoperative metastasis prediction based on portal vein circulating tumor cells detected by flow cytometry in periampullary or pancreatic cancer
title_full Postoperative metastasis prediction based on portal vein circulating tumor cells detected by flow cytometry in periampullary or pancreatic cancer
title_fullStr Postoperative metastasis prediction based on portal vein circulating tumor cells detected by flow cytometry in periampullary or pancreatic cancer
title_full_unstemmed Postoperative metastasis prediction based on portal vein circulating tumor cells detected by flow cytometry in periampullary or pancreatic cancer
title_short Postoperative metastasis prediction based on portal vein circulating tumor cells detected by flow cytometry in periampullary or pancreatic cancer
title_sort postoperative metastasis prediction based on portal vein circulating tumor cells detected by flow cytometry in periampullary or pancreatic cancer
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6689556/
https://www.ncbi.nlm.nih.gov/pubmed/31496801
http://dx.doi.org/10.2147/CMAR.S210332
work_keys_str_mv AT taolianyuan postoperativemetastasispredictionbasedonportalveincirculatingtumorcellsdetectedbyflowcytometryinperiampullaryorpancreaticcancer
AT suli postoperativemetastasispredictionbasedonportalveincirculatingtumorcellsdetectedbyflowcytometryinperiampullaryorpancreaticcancer
AT yuanchunhui postoperativemetastasispredictionbasedonportalveincirculatingtumorcellsdetectedbyflowcytometryinperiampullaryorpancreaticcancer
AT mazhaolai postoperativemetastasispredictionbasedonportalveincirculatingtumorcellsdetectedbyflowcytometryinperiampullaryorpancreaticcancer
AT zhanglingfu postoperativemetastasispredictionbasedonportalveincirculatingtumorcellsdetectedbyflowcytometryinperiampullaryorpancreaticcancer
AT boshiping postoperativemetastasispredictionbasedonportalveincirculatingtumorcellsdetectedbyflowcytometryinperiampullaryorpancreaticcancer
AT niuyunyun postoperativemetastasispredictionbasedonportalveincirculatingtumorcellsdetectedbyflowcytometryinperiampullaryorpancreaticcancer
AT lusijia postoperativemetastasispredictionbasedonportalveincirculatingtumorcellsdetectedbyflowcytometryinperiampullaryorpancreaticcancer
AT xiudianrong postoperativemetastasispredictionbasedonportalveincirculatingtumorcellsdetectedbyflowcytometryinperiampullaryorpancreaticcancer